Gynecologic cancers and in particular ovarian cancer are a major health problem in the United States. The Gynecologic Cancers Program seeks to improve methods of prevention, diagnosis and treatment of gynecologic cancers with a particular focus on ovarian cancer. The Program addresses all aspects of the disease, including underiying biology, molecular pathways, diagnostics and eariy detection, novel therapeutic targets, and clinical trials. Gynecologic cancers remain a major health problem in this country. In 2010, over 80,000 women will be diagnosed with a gynecologic cancer resulting in approximately 28,000 deaths. A disproportionate number of these deaths (14.000) result from ovarian cancer. This Program seeks to develop better strategies to detect diagnosis and treat women with these cancers. As a result, these efforts should improve both the survival and quality of life of women with gynecologic cancers.
The Specific Aims of the Gynecologic Cancers Program are: 1. To decipher the molecular events that are critical to the development of ovarian cancer, including testing whether a subset of ovarian cancers arise from the fallopian tube. 2. To discover and evaluate novel biomari
Public Health Relevance
Gynecologic cancers remain a major health problem in this country. In 2010, over 80,000 women will be diagnosed with a gynecologic cancer resulting in approximately 28,000 deaths. A disproportionate number of these deaths (14.000) result from ovarian cancer. This Program seeks to develop better strategies to detect diagnosis and treat women with these cancers. As a result, these efforts should improve both the survival and quality of life of women with gynecologic cancers.
|Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187|
|Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950|
|Francini, Edoardo; Gray, Kathryn P; Xie, Wanling et al. (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889-895|
|Hu, Yanhui; Vinayagam, Arunachalam; Nand, Ankita et al. (2018) Molecular Interaction Search Tool (MIST): an integrated resource for mining gene and protein interaction data. Nucleic Acids Res 46:D567-D574|
|Mohr, Stephanie E; Rudd, Kirstin; Hu, Yanhui et al. (2018) Zinc Detoxification: A Functional Genomics and Transcriptomics Analysis in Drosophila melanogaster Cultured Cells. G3 (Bethesda) 8:631-641|
|Odiaka, Emeka; Lounsbury, David W; Jalloh, Mohamed et al. (2018) Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP). J Glob Oncol :1-12|
|Mills, Evanna L; Pierce, Kerry A; Jedrychowski, Mark P et al. (2018) Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature 560:102-106|
|Oser, Matthew G; Fonseca, Raquel; Chakraborty, Abhishek A et al. (2018) Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov :|
|Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :|
|Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351|
Showing the most recent 10 out of 411 publications